The earnings call reflects a positive outlook with strong revenue growth, increased EBITDA, and successful product launches. However, challenges remain with declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment.

Company Guidance

During the third quarter of 2025, Kamada Ltd. reiterated its annual revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of between $40 million and $44 million, indicating double-digit growth over 2024 results. Total revenues for the first nine months of 2025 were $135.8 million, an 11% year-over-year increase, while adjusted EBITDA reached $34.2 million, up 35% year-over-year with a 25% margin of revenues. The company's growth strategy includes organic commercial growth, business development, and M&A transactions, alongside the advancement of pivotal programs such as their Phase III inhaled AAT study. Kamada's lead product, KedRAB, continues to have a strong market presence in the US and international markets. The distribution segment saw significant growth, supported by the launch of biosimilars in Israel, projected to contribute $15 million to $20 million in annual sales within five years. Kamada also highlighted its plasma collection operations, with FDA approval for its Houston facility and expected EMA inspection approvals. Meanwhile, the company is actively pursuing business development opportunities, with plans for compelling in-licensing collaborations and M&A transactions in 2026 to further enrich its portfolio.

Strong Revenue Growth

Total revenues for the first nine months of 2025 were $135.8 million, representing an 11% year-over-year increase. Q3 2025 revenues were $47 million, up 13% compared to Q3 2024.

Increased EBITDA

Adjusted EBITDA was $34.2 million for the first nine months of 2025, up 35% year-over-year, with a 25% margin of revenues.

Successful Product Launches

Launch of biosimilar products in Israel, contributing $2.5 million to revenue, with two more launches expected soon.

Plasma Collection Expansion

FDA approval for Houston plasma facility, with San Antonio expected in early 2026. Each site anticipated to generate $8-10 million annually at full capacity.

Promising Pipeline Developments

Advancement of Phase III clinical trial for inhaled AAT therapy, with futility analysis expected by the end of the quarter.

Kamada (KMDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KMDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 18, 2026	2025 (Q4)	0.08 / -	0.073	―	―	―
Nov 10, 2025	2025 (Q3)	0.09 / 0.09	0.074	24.32% (+0.02)	―
Aug 13, 2025	2025 (Q2)	0.09 / 0.13	0.084	57.14% (+0.05)	―
May 14, 2025	2025 (Q1)	0.07 / 0.07	0.044	65.91% (+0.03)	―
Mar 05, 2025	2024 (Q4)	0.05 / 0.07	0.097	-24.74% (-0.02)	―
Nov 13, 2024	2024 (Q3)	0.07 / 0.07	0.066	12.12% (<+0.01)	―
Aug 14, 2024	2024 (Q2)	0.06 / 0.08	0.045	86.67% (+0.04)
May 08, 2024	2024 (Q1)	0.06 / 0.04	0	―	―
Mar 06, 2024	2023 (Q4)	0.05 / 0.10	0.075	29.33% (+0.02)	―
Nov 13, 2023	2023 (Q3)	0.03 / 0.07	0.018	266.67% (+0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KMDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 10, 2025	$6.66	$7.02	+5.41%
Aug 13, 2025	$7.48	$7.38	-1.34%
May 14, 2025	$6.89	$7.05	+2.32%
Mar 05, 2025	$6.42	$6.90	+7.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kamada (KMDA) report earnings?

Kamada (KMDA) is schdueled to report earning on Mar 18, 2026, Before Open (Confirmed).

What is Kamada (KMDA) earnings time?

Kamada (KMDA) earnings time is at Mar 18, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KMDA EPS forecast?

KMDA EPS forecast for the fiscal quarter 2025 (Q4) is 0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing